# Morphotek clinical trials: 21 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Morphotek as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Morphotek: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/morphotek

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 6, 2015 | NCT02357147 | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural... | Morphotek | Phase 2 | Terminated | Mesothelioma, Malignant | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02357147) |
| January 4, 2013 | NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | Morphotek | Phase 1 | Completed | Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01761240) |
| December 12, 2012 | NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | Morphotek | Phase 1 | Completed | Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01748721) |
| April 10, 2012 | NCT01574716 | Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation | Morphotek | Phase 2 | Completed | Metastatic Soft Tissue Sarcoma | 209 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01574716) |
| January 30, 2012 | NCT01521325 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | Morphotek | Phase 1 | Completed | Mesothelioma, Pancreatic Cancer, Ovarian Cancer, Non-small Cell Lung Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01521325) |
| January 11, 2012 | NCT01507545 | Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) | Morphotek | Phase 2 | Terminated | Metastatic Colorectal Cancer, Colorectal Cancer | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01507545) |
| May 23, 2011 | NCT01357759 | Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects | Morphotek | Phase 1 | Completed | Rheumatoid Arthritis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01357759) |
| October 11, 2010 | NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | Morphotek | Phase 2 | Completed | Adenocarcinoma of the Lung | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01218516) |
| September 30, 2010 | NCT01212276 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | Morphotek | Phase 1 | Terminated | Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma, Melanoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01212276) |
| September 16, 2010 | NCT01203618 | Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas | Morphotek | Phase 2 | Withdrawn | Resectable, Non-functioning Pituitary Adenoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01203618) |
| May 14, 2010 | NCT01123304 | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma | Morphotek | Phase 1 | Terminated | Melanoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01123304) |
| November 23, 2009 | NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | Morphotek | Phase 2 | Terminated | Epithelial Ovarian Cancer | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01018563) |
| October 29, 2009 | NCT01004380 | Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer | Morphotek | Phase 1 | Completed | Epithelial Ovarian Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01004380) |
| February 24, 2009 | NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian... | Morphotek | Phase 3 | Terminated | Ovarian Cancer | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00849667) |
| February 19, 2009 | NCT00847054 | A Study of of MORAb-004 in Subjects With Solid Tumors | Morphotek | Phase 1 | Completed | Solid Tumor | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00847054) |
| August 20, 2008 | NCT00738699 | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer | Morphotek | Phase 2 | Terminated | Ovarian Cancer | 415 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00738699) |
| August 20, 2008 | NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma | Morphotek | Phase 2 | Completed | Malignant Pleural Mesothelioma | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00738582) |
| December 11, 2007 | NCT00570713 | An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer | Morphotek | Phase 2 | Completed | Pancreatic Cancer | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00570713) |
| January 30, 2007 | NCT00428766 | Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer | Morphotek | Phase 1 | Completed | Epithelial Ovarian Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00428766) |
| May 12, 2006 | NCT00325494 | A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer | Morphotek | Phase 1 | Completed | Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00325494) |
| April 26, 2006 | NCT00318370 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | Morphotek | Phase 2 | Completed | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00318370) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 2 | 10 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Terminated | 7 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Ovarian Neoplasms | 6 |
| Pancreatic Neoplasms | 4 |
| Carcinoma, Ovarian Epithelial | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Colorectal Neoplasms | 2 |
| Melanoma | 2 |
| Mesothelioma | 2 |
| Mesothelioma, Malignant | 2 |
| Lymphoma, Extranodal NK-T-Cell | 1 |
| Lymphoma, Large-Cell, Anaplastic | 1 |
| Immunoblastic Lymphadenopathy | 1 |
| Burkitt Lymphoma | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Intraocular Lymphoma | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Hodgkin Disease | 1 |
| Lymphoma, Large-Cell, Immunoblastic | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Dendritic Cell Sarcoma, Interdigitating | 1 |
| Lymphoma, T-Cell, Cutaneous | 1 |
| Lymphoma, Follicular | 1 |
| Lymphoma, Mantle-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Rail freight companies in the United States](https://specstream.ai/data/businesses/rail-freight-companies/united-states)
- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
- [Irish pubs in the United States](https://specstream.ai/data/businesses/irish-pubs/united-states)
- [Fondue restaurants in the United States](https://specstream.ai/data/businesses/fondue-restaurants/united-states)
- [Day care centers in the United States](https://specstream.ai/data/businesses/day-care-centers/united-states)
- [Blinds and shades companies in the United States](https://specstream.ai/data/businesses/blinds-and-shades-companies/united-states)
